Objective: Levels of the vascular peptide endothelin-1 (ET-1) are significantly elevated in obesity. Adipose tissue-derived ET-1 attenuates insulin-mediated antilipolysis in human visceral adipocytes through the activation of the ET receptor B (ET B R), thereby linking ET-1 to insulin resistance. Whether ET-1 has direct effects on lipolysis in human adipocytes is not known. Research design and subjects: Endothelin-1 receptor (ETR) mRNA expression was determined by quatitative PCR in 130 nonobese and obese subjects. ET-1 mRNA in different adipose tissue regions was also assessed. ETR protein expression was analyzed by western blotting in 37 subjects. The effect of ET-1 on lipolysis was assessed in freshly isolated adipocytes and in vitro differentiated adipocytes from human donors. Results: Freshly isolated human adipocytes incubated with different concentrations of ET-1 showed no acute effect on lipolysis. In contrast, a 24 h incubation in primary cultures of human adipocytes resulted in a significant 50% increase in lipolysis. This effect was concentration dependent and could be mimicked by an agonist of the ET A receptor but not with a selective ET B R agonist. Adipocyte differentiation was not affected by any of the agonists. In subcutaneous (s.c.) adipose tissue from 19 nonobese and 18 obese subjects, the protein expression of ET A R was significantly higher in obese subjects whereas there was no difference in ET B R expression. Interestingly, the differences in protein expression were not observed at the mRNA level as ET A R expression was similar between lean and obese subjects. Conclusion: Long-term but not acute incubation of human adipocytes with ET-1 results in a significant increase in lipolysis. This appears to be mediated through the activation of ET A R, demonstrating a yet another receptor-specific effect of ET-1. In addition, the protein expression of ET A R is increased in s.c. adipose tissue in obesity, possibly through post-transcriptional mechanisms. An increased effect of ET-1 could be a mechanism that contributes to increased basal lipolysis in human obesity.
Introduction
Obesity has long been recognized as a major risk factor for the development of insulin resistance, type 2 diabetes, dyslipidemia and cardiovascular disease. 1, 2 The release of free fatty acids from adipocytes (lipolysis) is increased in the obese state and is well known to play a major role in the development of obesity-associated complications. [3] [4] [5] Elevated circulating levels of free fatty acids increase hepatic lipogenesis, decrease glucose uptake in muscle and may also have deleterious effects on b-cell function in the pancreas. Lipolysis in human fat cells is primarily stimulated by catecholamines and natriuretic peptides and inhibited by insulin. 4 In obesity, a significant increase in non-stimulated (basal) lipolysis is observed. It has become evident that a number of factors produced locally in the fat tissue can regulate lipolysis through auto-and/or paracrine mechanisms. These substances are produced by the fat cells and/or the stroma vascular cells within the adipose tissue. 4 A number of these factors have been described in recent years including cytokines such as tumor necrosis factor-a and interleukin-6, fatty acid-derived molecules such as prostaglandins and small molecules such as adenosine. Fat cells are surrounded by stroma vascular cells in which endothelial cells are also present. One of the proteins secreted by endothelial cells is endothelin (ET), which is a potent vasoconstrictor involved in the regulation of blood pressure. ET exists in four isoforms (ET-1-3 and vasoactive intestinal contractor) out of which ET-1 is the best studied. 6 ET-1 binds to the Gq protein-coupled receptors ET receptor A (ET A R) and B (ET B R). This results in the activation of signaling pathways that include, phospholipase A 2 , phospholipase C and further downstream protein kinase C, calmodulin, phosphatidylinositol 3-kinase and mitogenactivated protein kinases. [6] [7] [8] [9] Receptors for ET-1 are expressed not only in smooth muscle cells but also in adipocytes and a number of other tissues. 6, 10 It has recently been shown that ET-1 is released by human subcutaneous (s.c.) adipose tissue and that its secretion is elevated in obesity. 10 Moreover, ET-1 attenuates the inhibit- ), we investigated whether ET-1 has any direct effects on lipolysis in primary cultures of human adipocytes. We also investigated the regional expression and the cellular origin of ET-1 and its receptors in human adipose tissue. Moreover, we analyzed the mRNA and protein levels of ET-1 receptors (ETRs) in lean and obese subjects.
Materials and methods

Subjects and tissue specimens
This study consisted of three groups of subjects. Group 1 was included for mRNA measurements to compare ET-1, ET A R and ET B R gene expression between adipose tissue regions, isolated adipocytes versus adipose tissue as well as ETR expression in non-obese and obese subjects. This cohort included 130 men and women, 108 obese and 22 non-obese, undergoing bariatric surgery or abdominal surgery for nonmalignant disorders, and has been described earlier in detail. 13 Group 2 was analyzed for ETR protein expression in obese versus non-obese subjects. This group included s.c. adipose tissue biopsies from 37 subjects undergoing bariatric or abdominal surgery for non-malignant disorders. Eighteen were obese and 19 were non-obese men and women. The effect of ET-1 on lipolysis in freshly isolated adipocytes and in vitro differentiated adipocytes was studied in a third cohort that included 27 subjects, 22 women and 5 men, undergoing either s.c. biopsies or abdominal surgery for non-malignant disorders. Body mass index (BMI) ranged from 20.4 to 51.4 kg/m 2 and age from 26 to 65 years. Adipose tissue samples were obtained at the beginning of the surgery under general anesthesia or under local anesthesia for s.c. biopsies. All subjects were otherwise healthy and not on any regular medication. No selection was made for age or gender. The study was approved by the Ethics Committee at Karolinska University Hospital, Huddinge. All subjects gave their informed consent to participate in the study.
Isolation of mature adipocytes and preadipocytes
Mature adipocytes and preadipocytes were isolated as described. 14 In brief, adipose tissue samples were cut into small pieces and incubated in the presence of collagenase for 1 h and then filtered twice through a nylon mesh. The mature adipocytes floated up in the filtrate, whereas the infranatant contained the stroma vascular fraction that included the preadipocytes. The freshly isolated adipocytes were washed several times and used immediately for lipolysis experiments. 15 The stroma vascular cells were washed and plated out at a density of 30 000 cells per cm 2 for the differentiation process. Cells were differentiated in a serumfree adipogenic culture medium described earlier supplemented with 10 mmol l À1 rosiglitazone for 6 days and maintained in the same adipogenic medium but without rosiglitazone until the cells had differentiated fully into adipocytes, which was approximately 12 days after the initiation of the differentiation process.
Lipolysis
Freshly isolated adipocytes were incubated at a density of 5000-10 000 cells per ml in Krebs Ringer Phosphate buffer (pH 7.4) supplemented with 2% bovine serum albumin, 1 mg l À1 glucose and 0.1 mg l À1 ascorbic acid in the presence or absence of 10 À12 -10 À7 M ET-1, for 2 h with air as the gas phase. For experiments with in vitro differentiated adipocytes, cells were washed and pre-incubated in Dulbecco's modified Eagle's medium/F12 for 2 h. This was followed by a 1-, 4-, 6-or 24 h incubation in Dulbecco's modified Eagle's medium/F12 supplemented with 2% bovine serum albumin in the presence or absence of 10
(an ET A R agonist) or BQ3020 (an ET B R agonist), respectively. In a set of experiments, cells were pre-treated as described above but incubated with or without isoprenaline (10
Glycerol concentration in the medium (an index of lipolysis) was determined. 16 Values were expressed as % of control for ET-1 and agonist experiments and as % of control at 1 h for the time-dependent experiments. The degree of differentiation in cell cultures was assessed by measuring glycerol-3-phosphate dehydrogenase activity as described.
14 Protein expression analysis Protein expression was determined by western blotting. For analyses in abdominal s.c. adipose tissue, approximately 300 mg was crushed and lysed in protein lysis buffer and homogenized using a microtome. Isolation of protein from in vitro differentiated adipocytes was performed as described earlier. 17 All steps were performed on ice to assure structural integrity of the proteins. Protein content was assayed using Blots were blocked for 1 h at room temperature in Trisbuffered saline containing 0.1% Tween 20 and 2% bovine serum albumin. This was followed by an overnight incubation at 41C in the presence of antibodies against ET A R, ET B R or b-actin (all from Sigma-Aldrich, St Louis, MO, USA). The antibodies directed against hormone-sensitive lipase, adipose triglyceride lipase and perilipin have been described earlier. 18 Secondary a-rabbit antibodies conjugated to horseradish peroxidase were from Sigma. Antigen-antibody complexes were detected by chemiluminisence (Lumiglo, Cell Signaling Technology Inc., Danvers, MA, USA) using a Chemidoc XRS system (Bio-Rad Laboratories Inc., Hercules, CA, USA) and specific bands were quantified using the Quantity One Software (Bio-Rad).
Gene expression
Total RNA was extracted using the Nucleospin RNA II kit (Macherey-Nagel, Düren, Germany) and reverse transcribed using the Omniscript RT kit (Qiagen, Hilden, Germany) and oligo(dT) primers (Invitrogen, Tåstrup, Denmark 
Results
Regional and cellular expression of ET-1 and ETRs
Endothelin-1 is released by human adipose tissue and its secretion is elevated in obesity. It is unknown whether there are regional differences in adipose ET-1 production. We compared ET-1 expression between abdominal s.c. and Endothelin-1 and human adipocyte lipolysis AKS Eriksson et al omental (OM) adipose tissue from 20 donors and found that s.c. tissue had significant higher mRNA levels than OM tissue ( Figure 1a ). In contrast, there was no statistically significant difference in ET A R or ET B R mRNA expression (P ¼ 0.62 and P ¼ 0.23, respectively) between the different fat depots (Figures 1b and c, respectively) . Adipose tissue is composed of several cell types among which the adipocytes represent B70% and the remaining cells are present in the stroma vascular portion (including adipocyte precursor cells, fibroblasts, leukocytes and endothelial cells). We investigated the expression of ET-1 in adipocytes and stroma vascular cells by comparing mRNA levels in isolated s.c. fat cells with those in adipose tissue from the same donors. Although adipocytes displayed detectable levels of ET-1 mRNA (Figure 1d ), ET-1 levels were considerably higher in adipose tissue. ET A R displayed a similar expressional pattern (P ¼ 0.017, Figure 1e ), whereas ET B R expression did not differ in the two preparations (Figure 1f ).
Lipolytic effects of ET-1 in human adipocytes
In an earlier study, we have shown that ET-1 induces insulin resistance in OM but not s.c. adipocytes after long-term incubations in vitro. 10 This leads indirectly to increased lipolysis in OM cells because of the reduced antilipolytic effect of insulin. However, given the recent findings demonstrating a direct lipolytic effect of ET-1 on rodent adipocytes, we assessed whether ET-1 may have similar direct effects in human adipocytes. We first tested the effect of a 2 h incubation with increasing concentrations of ET-1 on freshly isolated human adipocytes. Despite using a very sensitive method for glycerol detection we observed no significant effect (Figure 2a) . It is quite possible that the lack of effect could be due to the short incubation time. As freshly isolated fat cells in suspension have a very limited survival (hours), we performed additional experiments in cultures of in vitro differentiated human adipocytes. The effect of ET-1 was determined for up to 24 h. Although no effects of ET-1 were observed after shorter incubations (that is, 1 or 4 h), longer incubations (that is, 6 or 24 h) resulted in a 50% increase in glycerol release (n ¼ 6, Figure 2b , left panel). This was confirmed when we combined these results with results obtained in additional experiments performed at 24 h, which demonstrated the highly significant lipolytic effect of ET-1 (n ¼ 18, Figure 2b , right panel). Our cell cultures were clearly responsive to lipolytic stimulation as isoprenaline (a nonselective b-adrenoceptor agonist and a well-known lipolysis stimulator) stimulated lipolysis by 600% after 4 h (data not shown). The following experiments on ET-1 were performed at the 24 h time point. A significant concentration-dependent stimulation, starting at 1 nmol l
À1
, was observed (Figure 2c ). To determine whether the two ETRs may mediate the effect of ET-1 in a differential manner, we tested the action of ET A R and ET B R agonists. Although the ET B R agonist BQ3020 did not affect lipolysis, the ET A R agonist ET-1 caused a concentration-dependent increase after 24 h (Figure 2c ). These results suggest that it is primarily ET A R that mediates the effect of ET-1 on lipolysis. ET-1 is well known to inhibit adipocyte differentiation. To exclude the 
Endothelin-1 and human adipocyte lipolysis AKS Eriksson et al
possibility that the action of ET-1 on lipolysis was mediated through its effects on differentiation, we measured glycerol-3-phosphate dehydrogenase activity following the 24 h incubations using several concentrations of ET-1 or the selective ETR agonists. We observed no significant changes in glycerol-3-phosphate dehydrogenase activity (Figure 2d ).
In the same samples, we also analyzed the expression of proteins involved in regulating adipocyte lipolysis. However, a 24 h incubation with ET-1 had no effect on the expression of the rate-limiting lipase hormone-sensitive lipase, nor on the expression of adipose triglyceride lipase or perilipin (Figure 3a) .
The lipolytic effect of ET-1 correlates with BMI To assess whether there was any correlation between the in vitro activity of ET-1 with clinical correlates, we performed a regression analysis using the BMI of the adipocyte donors and the lipolytic effect of ET-1 in vitro. We found a positive and significant correlation (Figure 3b , r ¼ 0.44, Po0.05) that indicates that the lipolytic effect of ET-1 increases with obesity.
ETR expression in human adipose tissue
We compared protein and mRNA levels of the ETR isoforms between obese and non-obese subjects. Although ET A R expression was similar in lean and obese at the mRNA level (Figure 4a ), we observed a significantly higher expression in obese subjects at the protein level (Figure 4b ), suggesting that post-transcriptional mechanisms may influence ET A R levels. In contrast, ET B R mRNA was higher in the obese (Figure 4c ), but this was not observed at the protein level (Figure 4d ). It should be mentioned that although mRNA and protein measurements were performed in two different cohorts, subjects in the two groups were carefully matched for BMI, age and gender.
Discussion
Earlier studies in rodent adipocytes have shown that ET-1 increases adipocyte lipolysis in a time-and dose-dependent manner. In this study, we show that a similar albeit smaller effect is observed in human fat cells. This effect is only observed after 24 h. Incubations with receptor-specific agonists suggest that the lipolytic effect of ET-1 is mediated through the ET A R. It has earlier been shown that ET-1 inhibits the antilipolytic effect of insulin after long-term treatment of visceral adipocytes through the selective activation of ET B R. 10 Taken together, these results demonstrate that ET-1 can affect lipolytic regulation at several levels and through activation of different receptors. Earlier studies have shown that circulatory levels of ET-1 are increased in obesity. 10, [20] [21] [22] [23] [24] We have recently shown that s.c. adipose tissue, which is the major adipose region, might contribute to the elevated levels of ET-1 in the obese state. 10 This study shows that the expression of ET-1 mRNA is higher in s.c. adipose tissue compared with OM adipose tissue, whereas ETR expression is similar in the two depots . Expression analysis in cells from the different compartments in s.c. adipose tissue suggests that the major cellular source of ET-1 is present in the stroma vascular portion, mostly constituting endothelial cells. Although ET A R mRNA expression is also higher in tissues than in isolated cells, the difference is much less pronounced compared with that observed for the ET-1 levels. The lipolytic effect of ET-1 was observed only after 24 h of incubation. This suggests that the effect is dependent on changes in transcriptional regulation. Such effects on lipolysis are rather common in adipocytes and have earlier been shown for several cytokines including tumor necrosis factor-a and interleukin-6. 25 We studied the effect of ET-1 on protein levels of well-established regulators of lipolysis including perilipin, hormone-sensitive lipase, adipose triglyceride lipase (Figure 3a ) and phosphodiesterase-3 (PDE3) (not Endothelin-1 and human adipocyte lipolysis AKS Eriksson et al shown), but did not observe any significant differences in expression. Therefore, at present, we cannot define the mechanism through which ET-1 exerts its lipolytic effect. Using agonists specific for the two ETRs, we observed a lipolytic effect with the ET A R-specific agonist (ET-1[1-31]) but not with the ET B R-selective agonist (BQ3020). Although the specificity of ET-1[1-31] may not be entirely ET A R selective, 26 the lack of a lipolytic effect with BQ3020 argues for ET A R as the major mediator of lipolytic effect of ET-1 in s.c. adipocytes. Studies in rodent cells have shown that the effect of ET-1 is mediated through its binding to ET A R and downstream activation of extracellular signal-regulated kinase-1/2, which indicates that the lipolytic effect of ET-1 may be cyclic adenosine monophosphate independent. Furthermore, in contrast to our present findings in human cells, the lipolytic effect in rodent adipocytes is observed already after 4 h of incubation. We have studied the effect of extracellular signal-regulated kinase-1/2 inhibition in our human cell cultures using the same inhibitor (PD98059) as in the earlier rodent studies but unfortunately the antagonist displayed an intrinsic inhibition of basal lipolysis (unpublished data). Therefore, we cannot exclude the possibility that part of the effect may be mediated through extracellular signal-regulated kinase-1/2.
The maximum effect of ET-1 on lipolysis is observed at 10 nmol l
À1
. In our earlier study, 10 the same concentration induced the maximal inhibition on insulin's antilipolytic effect in visceral adipocytes. This concentration is much higher than the circulating levels of ET-1, which we have earlier shown to be in the picomolar range. 10 However, it is quite possible that the local concentration of ET-1 in adipose tissue may be significantly higher reaching the levels used in our assays. Assessing this in detail would require microdialysis, which, to our knowledge, has not yet been performed to measure ET-1.
In our earlier study, we observed important regional differences in the effect of ET-1 as the attenuating effect on insulin's antilipolytic effect was detected in OM but not s.c. adipocytes. In this study, we have almost entirely performed experiments on s.c. fat cells. This is due to the fact that visceral adipose tissue is increasingly more difficult to obtain due to the vast implementation of laparoscopic surgery in our country. It would, of course, have been of interest to determine whether similar effects are seen in OM cells.
It is well known that ET-1 attenuates adipocyte differentiation after long-term incubations. 10 In this study, using relatively short incubations (max 24 h), we observed no negative (nor positive) effect on differentiation assessed by glycerol-3-phosphate dehydrogenase activity. This precludes the possibility that any of the observed effects in our study are secondary to the effects on differentiation. We obtain adipose tissue from subjects undergoing surgery for non-malignant diseases. We practiced no a priori selection of individuals and isolated cells from both lean and obese subjects. However, when we plotted the lipolytic effect of Endothelin-1 and human adipocyte lipolysis AKS Eriksson et al ET-1 in vitro with the BMI of the donor, we observed a significant positive correlation. This suggests that fat cells from obese subjects are more sensitive to the lipolytic effect of ET-1. Moreover, as this effect was observed in fat cells differentiated in vitro, it is quite possible that the increased sensitivity to ET-1 may be genetically defined. This notion is based on the fact that the preadipocytes are differentiated in vitro for 2 weeks without any exogenous influence from other surrounding cells or possible mediators in the circulation. This increased lipolytic effect may be secondary to the increased protein levels of ET A R, which we observed in white adipose tissue (WAT) of obese subjects. However, we cannot exclude other changes in downstream signaling mechanisms. Curiously, we observed no difference in ET A R mRNA levels. Conversely and in contrast to ET A R, ET B R mRNA levels were higher in obese subjects, whereas protein levels were similar in s.c. WAT from lean and obese donors. The discrepancies between ETR mRNA and protein expression suggest that the expression of these receptors are influenced by post-transcriptional mechanisms. These may include effects on mRNA stability and/or protein half-life. Given the increased effect of ET-1 in obesity and the lack of a compensatory ETR downregulation (as commonly observed when agonist concentrations are high), it could be speculated that individuals who develop obesity may have a defect in the post-transcriptional downregulation of ET A R expression. This results in increased lipolysis and elevated circulating fatty acid levels leading to insulin resistance. We admit that this notion is purely speculative and that our present data cannot prove this concept. In conclusion, ET-1 produced in the stroma vascular portion of WAT is expressed at higher levels in the s.c. region. ET-1 exerts a lipolytic effect in human adipocytes, most probably through its effects on gene regulation. Moreover, obese subjects display a more pronounced response to ET-1 possibly due to an increased expression of ET A R in obesity. The expression of ET A R appears to be post-transcriptionally regulated as ET A R mRNA levels were not influenced by obesity. Taken together, our present data and earlier published studies in human fat cells demonstrate that ET-1 exerts differential effects on lipolysis. In visceral fat, this is mediated through the activation of ET B R, resulting in the inhibition of insulin's antilipolytic effect. In contrast, in s.c. fat, this appears to be mediated through ET A R, resulting in a more direct activation of lipolysis. ET-1 may therefore play an important modulatory role in fat cell function in vivo.
